Logo image of ALAB

ASTERA LABS INC (ALAB) Stock Fundamental Analysis

NASDAQ:ALAB - Nasdaq - US04626A1034 - Common Stock - Currency: USD

54.745  -4.22 (-7.15%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ALAB. ALAB was compared to 109 industry peers in the Semiconductors & Semiconductor Equipment industry. While ALAB has a great health rating, there are worries on its profitability. While showing a medium growth rate, ALAB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALAB had positive earnings in the past year.
In the past year ALAB had a positive cash flow from operations.
ALAB Yearly Net Income VS EBIT VS OCF VS FCFALAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -7.91%, ALAB is doing worse than 72.48% of the companies in the same industry.
Looking at the Return On Equity, with a value of -8.65%, ALAB is doing worse than 70.64% of the companies in the same industry.
Industry RankSector Rank
ROA -7.91%
ROE -8.65%
ROIC N/A
ROA(3y)-16.28%
ROA(5y)N/A
ROE(3y)-19.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALAB Yearly ROA, ROE, ROICALAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -10 -20 -30

1.3 Margins

The Gross Margin of ALAB (76.38%) is better than 95.41% of its industry peers.
ALAB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.38%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALAB Yearly Profit, Operating, Gross MarginsALAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

ALAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALAB has been increased compared to 1 year ago.
ALAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALAB Yearly Shares OutstandingALAB Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 50M 100M 150M
ALAB Yearly Total Debt VS Total AssetsALAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ALAB has an Altman-Z score of 64.73. This indicates that ALAB is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 64.73, ALAB belongs to the top of the industry, outperforming 99.08% of the companies in the same industry.
There is no outstanding debt for ALAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 64.73
ROIC/WACCN/A
WACC10.99%
ALAB Yearly LT Debt VS Equity VS FCFALAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 11.71 indicates that ALAB has no problem at all paying its short term obligations.
ALAB has a better Current ratio (11.71) than 97.25% of its industry peers.
ALAB has a Quick Ratio of 11.21. This indicates that ALAB is financially healthy and has no problem in meeting its short term obligations.
ALAB has a better Quick ratio (11.21) than 97.25% of its industry peers.
Industry RankSector Rank
Current Ratio 11.71
Quick Ratio 11.21
ALAB Yearly Current Assets VS Current LiabilitesALAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

ALAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -269.05%.
The Revenue has grown by 242.24% in the past year. This is a very strong growth!
EPS 1Y (TTM)-269.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)242.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ALAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.25% yearly.
The Revenue is expected to grow by 46.02% on average over the next years. This is a very strong growth
EPS Next Y28.58%
EPS Next 2Y32.34%
EPS Next 3Y36.25%
EPS Next 5YN/A
Revenue Next Year76.09%
Revenue Next 2Y52.29%
Revenue Next 3Y46.02%
Revenue Next 5YN/A

3.3 Evolution

ALAB Yearly Revenue VS EstimatesALAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
ALAB Yearly EPS VS EstimatesALAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0.5 1 1.5 2 2.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 54.74, which means the current valuation is very expensive for ALAB.
The rest of the industry has a similar Price/Earnings ratio as ALAB.
The average S&P500 Price/Earnings ratio is at 28.29. ALAB is valued rather expensively when compared to this.
ALAB is valuated quite expensively with a Price/Forward Earnings ratio of 42.58.
ALAB's Price/Forward Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.32, ALAB is valued quite expensively.
Industry RankSector Rank
PE 54.75
Fwd PE 42.58
ALAB Price Earnings VS Forward Price EarningsALAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

ALAB's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 86.66
EV/EBITDA N/A
ALAB Per share dataALAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ALAB does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as ALAB's earnings are expected to grow with 36.25% in the coming years.
PEG (NY)1.92
PEG (5Y)N/A
EPS Next 2Y32.34%
EPS Next 3Y36.25%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASTERA LABS INC

NASDAQ:ALAB (4/21/2025, 11:24:54 AM)

54.745

-4.22 (-7.15%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)02-10 2025-02-10/amc
Earnings (Next)05-06 2025-05-06
Inst Owners69.03%
Inst Owner Change0.21%
Ins Owners16.17%
Ins Owner Change-5.92%
Market Cap8.88B
Analysts83
Price Target125.1 (128.51%)
Short Float %7.01%
Short Ratio1.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.21%
Min EPS beat(2)32.36%
Max EPS beat(2)40.06%
EPS beat(4)4
Avg EPS beat(4)162.51%
Min EPS beat(4)15.86%
Max EPS beat(4)561.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)10.93%
Min Revenue beat(2)8.09%
Max Revenue beat(2)13.78%
Revenue beat(4)4
Avg Revenue beat(4)9.67%
Min Revenue beat(4)3.98%
Max Revenue beat(4)13.78%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.69%
PT rev (3m)14.18%
EPS NQ rev (1m)-0.12%
EPS NQ rev (3m)10.47%
EPS NY rev (1m)0.06%
EPS NY rev (3m)6.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)13.91%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)10.06%
Valuation
Industry RankSector Rank
PE 54.75
Fwd PE 42.58
P/S 22.4
P/FCF 86.66
P/OCF 64.95
P/B 9.2
P/tB 9.2
EV/EBITDA N/A
EPS(TTM)1
EY1.83%
EPS(NY)1.29
Fwd EY2.35%
FCF(TTM)0.63
FCFY1.15%
OCF(TTM)0.84
OCFY1.54%
SpS2.44
BVpS5.95
TBVpS5.95
PEG (NY)1.92
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.91%
ROE -8.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.38%
FCFM 25.85%
ROA(3y)-16.28%
ROA(5y)N/A
ROE(3y)-19.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 1085.76%
Cap/Sales 8.64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.71
Quick Ratio 11.21
Altman-Z 64.73
F-Score6
WACC10.99%
ROIC/WACCN/A
Cap/Depr(3y)573.57%
Cap/Depr(5y)N/A
Cap/Sales(3y)5.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-269.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y28.58%
EPS Next 2Y32.34%
EPS Next 3Y36.25%
EPS Next 5YN/A
Revenue 1Y (TTM)242.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year76.09%
Revenue Next 2Y52.29%
Revenue Next 3Y46.02%
Revenue Next 5YN/A
EBIT growth 1Y-293.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year129.67%
EBIT Next 3Y66.85%
EBIT Next 5YN/A
FCF growth 1Y761.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1174.83%
OCF growth 3YN/A
OCF growth 5YN/A